Skip to content
2000
Volume 9, Issue 1
  • ISSN: 1574-3624
  • E-ISSN: 2212-389X

Abstract

Growth factor signaling via receptor tyrosine kinases plays a central role in initiating and maintaining a malignant phenotype. Fibroblast growth factors (FGF) and their receptor family (FGFR1-4) are key players in various human solid and hematological tumors and have been linked to tumor cell proliferation, resistance to chemotherapy and apoptosis, angiogenesis, invasion and metastasis. FGFRs are commonly activated by genomic alterations or mutations and various approaches to targeted inhibition have been developed. The deeper understanding of the underlying signal transduction mechanisms has generated novel targeted therapy approaches like ligand-traps, receptor-specific antibodies or small molecule kinase inhibitors that are currently undergoing preclinical and clinical development for the treatment of human cancers.

Loading

Article metrics loading...

/content/journals/cst/10.2174/157436240901140924103836
2014-04-01
2025-10-02
Loading full text...

Full text loading...

/content/journals/cst/10.2174/157436240901140924103836
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test